- Home
- »
- Medical Devices
- »
-
Pain Management Devices Market Size Report, 2026-2033GVR Report cover
![Pain Management Devices Market (2026 - 2033)Report]()
Pain Management Devices Market (2026 - 2033)
Size, Share & Trends Analysis Report By Application (Neuropathic, Cancer), By Product (Electrical Stimulators, Radiofrequency Ablation, Analgesic Infusion Pump), By End Use, By Region, And Segment Forecasts
Market Size, 2025
$8.4BMarket Estimate, 2026
$9.2BMarket Forecast, 2033
$16.8BCAGR, 2026–2033
8.9%Pain Management Devices Market Summary
The global pain management devices market size was valued at USD 8.4 billion in 2025 and is projected to grow from USD 9.2 billion in 2026 to USD 16.8 billion by 2033, at a CAGR of 8.9% from 2026 to 2033. North America dominated the pain management devices market with the largest revenue share of 47.5% in 2025. The growing prevalence of chronic conditions is one of the key aspects anticipated contributing to the market growth during the forecast period.
Key Market Trends & Insights
- By product: Neurostimulation products segment held the largest market share of 57.8% in 2025.
- By application: Neuropathic pain segment held the largest market share of 32.1% in 2025.
- By end use: Hospitals & clinics segment held the largest market share of 29.8% in 2025.
Regional Highlights
- Largest regional market: North America (47.5% revenue share, 2025)
- By country: The U.S. held the largest market share in 2025
Market Size & Forecast
- Market size in 2025: USD 8.4 Billion
- Estimated market size in 2026: USD 9.2 Billion
- Projected market size by 2033: USD 16.8 Billion
- CAGR (2026-2033): 8.9%
The increasing prevalence of lifestyle diseases, such as diabetes and obesity, has boosted the demand for nerve and muscle stimulators. The rising prevalence of hypertension or trauma is another significant factor expected to propel market growth. Hypertension significantly raises the risk of chronic conditions, such as brain aneurysms. As per the WHO report for 2024, nearly 1 in 3 adults worldwide is affected by hypertension, with a slightly greater prevalence in males than females in the under 50 age group. After age 50, the prevalence climbs to nearly 49%, indicating that about 1 in 2 individuals are affected, with both men and women exhibiting almost the same rates of hypertension.
In addition, rolling issues of musculoskeletal conditions, such as osteoarthritis, orthopedic degenerative diseases, arthritis, and rheumatoid arthritis, are rising significantly. This has increased the prevalence of chronic pain in these people and the inability to carry out everyday chores. For instance, based on the research published by Elsevier B.V. in 2024, the prevalence of osteoarthritis (OA) is persistently rising around the world, influencing nearly 7.6% of the global population, with estimates suggesting a 60 to 100% increase by the year 2050. Furthermore, OA stands as the seventh leading cause of disability on a global scale for individuals over the age of 70, primarily affecting the knee joints. This has propelled the market for pain management stimulators to control chronic pain. In addition, an upsurge in the number of accident cases, obesity, bone-related diseases, and the comfort of advanced procedures are also anticipated to promote market expansion.
Obesity is the primary cause of arthritis. In 2024, the NCD Risk Factor Collaboration (NCD-RisC) released findings indicating that over one billion individuals worldwide are currently affected by obesity, which includes nearly 880 million adults, and 159 million children and adolescents aged 5 to 19 years. Moreover, according to the CDC, 31% of people with obesity have arthritis, compared to 23% of people who are overweight and 16% of people who are underweight or have a moderate BMI. In addition, as per the Cary Orthopaedics report, every pound of extra weight exerts nearly 4 to 6 pounds of additional pressure on the knees. The inefficacy of oral drugs is encouraging patients to look for other available treatment alternatives, such as pain control devices. Many individuals are addicted to painkillers. However, these medications show side effects and are sometimes inefficient. Furthermore, the lack of choice options for surgeries is one of the aspects of increasing the demand.
The WHO report released in 2022 indicates that more than 24% of individuals suffering from healthcare-associated sepsis die annually, while 52.3% of those receiving treatment in an intensive care unit die each year. The increased hospitalization expenses have boosted the need for shorter hospital stays and affordable care settings, thus growing the market demand. For instance, according to the article by Debt.Org, LLC published in March 2023, the average daily cost of hospitalization in the U.S. is approximately USD 2,883, and the average length of a hospital stay is about 4.6 days, resulting in an average total expense of USD 13,262.
Technological advances are also expected to propel market growth. For instance, in July 2024, Stryker introduced its MultiGen 2 Radiofrequency (RF) Generator, which offers physicians the efficiency, control, and reliability necessary for conducting RF ablation, a minimally invasive technique that can deliver long-term relief for individuals experiencing facet joint pain. In February 2024, Boston Scientific Corporation announced that the U.S. Food and Drug Administration (FDA) has granted an expanded indication for the WaveWriter SCS Systems, allowing it to treat chronic low back and leg pain in individuals who have not undergone previous back surgery, a condition typically known as non-surgical back pain (NSBP).
Market Dynamics
The growing prevalence of chronic conditions is one of the key drivers contributing to the market growth during the forecast period. The increasing prevalence of lifestyle diseases, such as diabetes and obesity, has boosted the demand for nerve and muscle stimulators. The rising prevalence of hypertension or trauma is another significant factor expected to propel market growth.
The rising prevalence of chronic pain disorders is a major driver of growth in the global pain management devices market. Conditions such as chronic lower back pain, neuropathic pain, cancer-related pain, musculoskeletal disorders, arthritis, and post-surgical pain continue to affect a large patient population worldwide, creating sustained demand for effective pain management solutions. For instance, according to the World Health Organization (WHO), around 1 in 3 people are currently living with neurological conditions. Conventional pharmacological therapies, particularly opioid-based treatments, have been associated with risks including dependency, tolerance, and adverse side effects, prompting healthcare providers to seek alternative treatment approaches. Similarly, according to data published by the U.S. CDC in November 2024, 4.3% of adults had chronic pain, and 8.5% had high-impact chronic pain. Pain management devices such as spinal cord stimulators, radiofrequency ablation systems, transcutaneous electrical nerve stimulation (TENS) devices, and infusion pumps offer targeted pain relief while reducing reliance on long-term drug therapy.
The growing burden of chronic diseases and age-related degenerative conditions has further increased the number of patients requiring long-term pain management interventions. In addition, greater awareness among physicians and patients regarding minimally invasive pain treatment options has supported broader adoption of device-based therapies. As healthcare systems increasingly focus on improving patient outcomes and quality of life, demand for advanced pain management technologies continues to expand across hospitals, ambulatory surgical centers, and specialty pain clinics.
Healthcare providers are increasingly incorporating neurostimulation and other advanced pain management technologies into treatment pathways, as these technologies are able to improve mobility, reduce pain intensity, and enhance patient satisfaction. The expanding clinical evidence supporting the safety and effectiveness of these devices has also strengthened physician confidence and adoption rates. As the global prevalence of chronic pain continues to rise, the demand for innovative pain management devices is expected to remain a key driver of market growth.
The high cost of advanced pain management devices and related procedures is a primary restraint on market growth. Technologies such as spinal cord stimulators, deep brain stimulators, sacral neurostimulators, radiofrequency ablation systems, and implantable infusion pumps often involve substantial upfront costs, including device acquisition, surgical implantation, programming, follow-up care, and maintenance. These expenses create financial challenges for healthcare providers and patients, particularly in regions with limited healthcare funding or inadequate reimbursement coverage. Although these devices provide long-term pain relief and improve patient outcomes, the initial investment required for treatment is likely to discourage adoption among cost-sensitive patient populations.
Item/Cost Factor
Cost Estimate
Fluoroscopy Equipment (New)
USD 75,000 - USD 150,000
Fluoroscopy Equipment (Used)
USD 25,000 - USD 50,000
Ultrasound Guidance Systems
USD 15,000 - USD 35,000
Basic Injection Supplies and Medications
USD 500 - USD 1,000 per month
Staff Training and Certification Costs
USD 2,000 - USD 10,000 per provider
Healthcare facilities must also allocate resources for specialized equipment, physician training, and post-procedure monitoring, further increasing the overall cost burden. In developing and emerging economies, affordability concerns often limit access to advanced pain management technologies, resulting in continued reliance on conventional pharmacological treatments. Thus, the high economic burden associated with device-based pain therapies remains a key factor restricting broader market penetration.
Market Concentration And Characteristics
The degree of innovation in pain management devices has significantly advanced in recent years, driven by the need for more effective, safer, and personalized solutions. Traditional pain management methods, such as oral medications and injections, are increasingly being supplemented or replaced by non-invasive and minimally invasive technologies that provide more targeted and sustainable relief.
The pain management devices market is characterized by a medium level of merger and acquisition (M&A) activity. These M&A activities enable access to complementary expertise, technologies, and various distribution channels, enabling companies to enhance operational efficiency, accelerate product development, and capture a larger market share.
The impact of regulations on pain management devices is significant, as regulatory bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) play a critical role in ensuring the safety, efficacy, and quality of these devices. Stringent regulatory requirements for clinical testing, pre-market approval, and post-market surveillance help ensure that pain management devices, such as implantable drug delivery systems, neuromodulation devices, and PCA pumps, meet high standards before reaching patients.
Pharmaceutical interventions, particularly opioids, NSAIDs (non-steroidal anti-inflammatory drugs), and acetaminophen, are the most common alternatives to devices, providing systemic pain relief, though with concerns about side effects, addiction, and long-term use. For chronic pain management, topical analgesics, including creams, patches, and gels that deliver pain-relieving compounds directly to the site of discomfort, serve as a non-invasive option.
Analyst Perspective
The global pain management devices market is experiencing sustained growth due to the rising prevalence of chronic pain disorders, musculoskeletal conditions, neuropathic pain, arthritis, spinal disorders, and cancer-related pain. Concerns regarding long-term opioid use are accelerating the adoption of minimally invasive, non-pharmacological device-based therapies. Healthcare providers are increasingly utilizing neurostimulation, radiofrequency ablation, infusion pumps, and wearable pain relief technologies to improve patient outcomes. Advancements in neuromodulation, digital health integration, and personalized pain therapies are enhancing treatment precision and patient satisfaction, while the shift toward outpatient and home-based care is driving demand for remotely managed solutions. Companies with strong clinical evidence, advanced technologies, and comprehensive product portfolios are well positioned to capitalize on long-term growth opportunities in the global pain management devices market.
Recent Developments in the Pain Management Devices Market
Sr. No.
Company
Month/Year
Description
1
Litemed India Private Limited
June 2026
Hyderabad-based health-tech startup Litemed India Private Limited received CDSCO Class II Medical Device approval for CURAPOD, India's first non-invasive personalized pain management wearable. CURAPOD uses clinically validated photobiomodulation technology delivering medical-grade red and near-infrared light to promote cellular repair, reduce inflammation, and accelerate recovery.
2
Medtronic
May 2026
Medtronic announced its intent to acquire SPR Therapeutics for USD 650 million in cash, adding the FDA-cleared SPRINT Peripheral Nerve Stimulation (PNS) System to its neuromodulation portfolio.
3
Trice Medical
March 2026
Trice Medical announced nationwide commercial availability of the FDA-cleared Tenex 2nd Generation System, expanding minimally invasive ultrasonic treatment for chronic tendon disease and musculoskeletal conditions. The system features FDA 510(k) clearance, introducing two longer MicroTip ultrasonic handpieces to reach deeper anatomical structures such as the shoulder and hip, improved power settings, and enhanced aspiration/irrigation controls via a redesigned console.
4
Innovative Medical Equipment, LLC
February 2026
Innovative Medical Equipment, LLC (IME), manufacturer of ThermaZone, debuted its ThermaZone LSO Heating and Cooling Back Braces at Medtrade 2026, combining structured lumbosacral support with integrated thermal therapy for non-pharmacological pain management.
5
Nalu Medical
August 2025
Nalu Medical launched a 39% smaller Therapy Disc, an external wearable device for its FDA-cleared Nalu Neurostimulation System that powers an implantable micro-IPG for peripheral nerve stimulation (PNS) therapy. The smaller, discreet wearable improves comfort and accessibility for patients with chronic nerve pain, eliminating the need for implanted batteries and reducing surgical burden.
6
Meliodays Medical and Celanese Corporation
July 2025
Meliodays Medical and Celanese signed a partnership agreement to develop MelioOne®, the first hormone-free, non-contraceptive IUD for treating menstrual pain using targeted, localized drug delivery.
“More than 80% of menstruating people experience period pain and cramps. Our partnering with Celanese marks the first milestone in achieving our mission to address menstrual pain management solutions. Our localized release targets pain at its source, avoiding the systemic side effects often associated with oral intake of pain medication”
- Simone Sabbione, CEO and Co-Founder of Meliodays.
7
Neuros Medical
July 2025
Neuros Medical closed an oversubscribed USD 56 million Series D financing round to support U.S. commercialization and development of the Altius Direct Electrical Nerve Stimulation System, an FDA-approved, breakthrough non-opioid treatment for chronic post-amputation pain.
Source: Secondary Research, Grand View Research
Product Insights
By product, the neurostimulation products segment held the largest market share of 57.8% in 2025. The dominance can be attributed to the rise in the cases of neurological diseases. These neurostimulators are essential in treating Parkinson’s, epilepsy, chronic pain, movement diseases, and depression. Moreover, factors, such as the launch of cutting-edge products, growing product demand, and the rising geriatric population, are expected to drive the market. According to data from UNFPA, the worldwide percentage of individuals aged 65 and older has almost doubled, rising from 5.5% in 1974 to 10.3% in 2024. It is anticipated that this percentage will increase to 20.7% by 2074, with the population of those aged 80 and above more than tripling. The growing aging population is projected to propel the market, as the aged population is at a tremendous risk of chronic disease.
However, the radiofrequency Ablation systems segment is anticipated to witness the fastest growth with a CAGR over the forecast period, owing to its vast application in pain management, gynecology, surgical oncology, cosmetology, cardiology & cardiac rhythm management. Radiofrequency ablation treatment is more helpful in treating patients with numerous tumors than patients via open surgery, thus boosting segment growth.
Application Insights
By application, neuropathic pain segment held the largest market share of 32.1% in 2025. The dominance can be attributed to the growing initiatives by the industry players and the rising number of target individuals. As stated in a report from the National Library of Medicine in 2024, more than twenty-five percent of individuals in the United States experience chronic pain, which is one of the most common problems faced in outpatient medical environments. Similarly, the British Pain Society 2024 reports that in England, approximately 28 million adults, which is around 43% of the population, experience chronic pain. The factors mentioned above are anticipated to fuel growth.
However, the cancer segment is expected to register fastest growth over the forecast period. The growing number of cancer patients has augmented the need for pain management devices to alleviate the pain caused owing to nerve compression, primarily because of the tumor compressing and other variables relying upon cancer’s advancement. In addition, most genetic disorders, such as Acute Lymphoblastic Leukemia (ALL), are projected to propel the market demand over the forecast period. The National Cancer Institute projects about 2,001,140 new cancer diagnoses in the United States for 2024, with an estimated 611,720 deaths due to the illness.
End Use Insights
By end use the hospitals and clinics segment held the largest market share of 29.8% in 2025. The increasing prevalence of chronic pain conditions, such as arthritis, musculoskeletal disorders, and neuropathic pain, is resulting in a higher number of patients who require effective pain management solutions. Hospitals and clinics are at the forefront of providing medical treatments, and as the population ages and chronic diseases become more common, the demand for advanced pain management technologies is growing. Additionally, hospitals and clinics are increasingly investing in cutting-edge technologies that offer targeted pain relief, improve recovery times, and reduce hospital readmissions. Furthermore, the rising number of hospitals worldwide is also contributing to market growth. For instance, according to the 2022 AHA Annual Survey, there were a total of 6,120 hospitals in the U.S.
However, the outpatient facilities segment and is expected to witness the fastest growth during the forecast period from 2026 to 2033. The physiotherapy centers segment is anticipated to grow at the fastest CAGR during the forecast period owing to the increasing focus on non-invasive, drug-free treatments for musculoskeletal pain and rehabilitation. Furthermore, rapid development of new technologies, such as wearable devices and smart pain management systems, is enhancing the effectiveness and convenience of pain treatment in physiotherapy centers. Moreover, increasing cases of sports-related injuries across the globe is anticipated to boost market growth. According to a report from Johns Hopkins University, approximately 30 million children and teenagers engage in various organized sports, leading to over 3.5 million injuries each year.
Regional Insights
North America dominated the pain management devices market with the largest revenue share of 47.5% in 2025 owing to the advanced healthcare infrastructure enabling easy access to cutting-edge pain management devices. In addition, the regional market is driven by factors, such as the presence of established healthcare facilities, a growing geriatric population, and a high prevalence of stroke & hypertension.
U.S. Pain Management Devices Market Trends
The pain management devices market in the U.S. held the largest share in the North America region in 2025. Presence of extensive public & private funding initiatives, especially in the U.S., to create awareness regarding advanced devices. These initiatives, including the U.S. Affordable Care Act (ACA), focus on reducing the cost of medical devices.
Europe Pain Management Devices Market Trends
Europe pain management devices market is anticipated to register a significant growth rate during the forecast period. The presence of market players such as B. Braun Melsungen AG and Medtronic is expected to boost market growth.Increasing awareness regarding chronic pain disorders and pain management devices for treatment is expected to propel market growth.
Germany pain management devices market is anticipated to register a considerable growth rate during the forecast period. This can be attributed to the large population suffering from different musculoskeletal disorders and the high adoption of advanced technologies & devices.
The pain management devices market in UK is anticipated to register a considerable growth rate during the forecast period. Rising demand for noninvasive treatment procedures and growing prevalence of musculoskeletal diseases, such as bone degenerative diseases & osteoarthritis, are expected to drive market growth.
Asia Pacific Pain Management Devices Market Trends
The Asia Pacific pain management devices is expected to witness the fastest growth over the forecast period. Increasing adoption of pain management devices due to growing awareness about them is expected to boost regional growth.Moreover, the rising prevalence of obesity and other lifestyle disorders, which lead to an increase in the incidence of chronic pain disorders, is expected to boost market growth.
The India pain management devices market is anticipated to register the fastest growth rate during the forecast periodowing to increasing geriatric population. According to the report by NITI Aayog from the Government of India released in 2024, senior citizens currently make up slightly more than 10% of India's population, which equates to approximately 104 million people. It is anticipated that this percentage will rise to 19.5% of the total population by the year 2050.
The pain management devices market in China is anticipated to register the fastest growth rate during the forecast periodowing to increasing geriatric population owing to the country's large and aging population, rising prevalence of chronic conditions, and increasing healthcare infrastructure development.
Latin America Pain Management Devices Market Trends
The Latin America pain management devices market is anticipated to register a considerable growth rate during the forecast period. The rising adoption of advanced medical technologies and the shift towards non-invasive,drug-free pain management solutions are key factors propelling market growth.
Brazil pain management devices market is anticipated to register a considerable growth rate during the forecast period owing to an increasing healthcare spending, expanding private healthcare facilities, and a growing demand for non-pharmaceutical pain treatments.
Middle East & Africa Pain Management Devices Market Trends
The Middle East and Africa regions are experiencing lucrative growth in the pain management devices market. High disposable incomes, advanced healthcare infrastructure, and increasing patient awareness about non-pharmacological pain relief methods are fostering market growth.
South Africa pain management devices market is anticipated to register a considerable growth rate during the forecast period owing tohigh burden of chronic diseases, including musculoskeletal and neuropathic disorders. Additionally, improving healthcare infrastructure and greater awareness about chronic pain management are supplementing market growth.
Key Pain Management Devices Company Insights
Key participants in the market focus on developing innovative business growth strategies through mergers and acquisitions, partnerships and collaborations, product portfolio expansions, and business footprint expansions.
Key Pain Management Devices Companies:
The following key companies have been profiled for this study on the pain management devices market.
-
B Braun Melsungen AG
-
Baxter
-
Boston Scientific Corporation or its affiliates
-
Nevro Corp.
-
Enovis
-
OMRON Healthcare INC
-
Medtronic
-
ICU Medical Inc
-
Abott
-
Stryker
-
Stimwave LLC
Competitive Benchmarking
Category
Operating Strategies
Competitive Edge
Weakness
Established Players (Medtronic, Boston Scientific Corporation, Abbott, Baxter, B. Braun Melsungen AG, Stryker)
- Expand pain management device portfolios through continuous product innovation, strategic acquisitions, global distribution network expansion, and partnerships with hospitals, pain clinics, ambulatory surgery centers, and healthcare providers. Invest in spinal cord stimulation (SCS) systems, radiofrequency ablation technologies, infusion pumps, neuromodulation platforms, AI-enabled programming solutions, and minimally invasive pain management technologies to strengthen market leadership. Focus on improving patient outcomes through advanced neurostimulation systems, personalized therapy programming, remote monitoring capabilities, and integrated digital health solutions.
- Strong global brand recognition, extensive clinical validation, broad pain management and medical device portfolios, and well-established relationships with healthcare providers and reimbursement stakeholders. Significant R&D capabilities, regulatory expertise, large-scale manufacturing infrastructure, and comprehensive sales networks enable broad market penetration across chronic pain, neuropathic pain, musculoskeletal pain, and postoperative pain applications.
- High product development, clinical trial, and regulatory compliance costs can impact profitability and pricing flexibility. Premium-priced neuromodulation systems and advanced pain management devices may face adoption challenges in cost-sensitive healthcare markets. Reimbursement limitations and complex approval pathways can also affect commercialization and market expansion.
Emerging & Specialized Players (Nevro Corp., Enovis, OMRON Healthcare Inc., ICU Medical Inc.)
- Focus on specialized pain management technologies such as high-frequency spinal cord stimulation, wearable pain relief devices, peripheral nerve stimulation systems, infusion technologies, and non-invasive pain management solutions. Leverage niche expertise, flexible product development, patient-centric innovation, and targeted market expansion strategies to strengthen competitive positioning and address specific chronic pain management needs.
- Greater agility in responding to evolving clinical requirements and technological advancements within specialized pain management segments. Ability to introduce innovative therapies more rapidly, provide focused clinical support, offer differentiated treatment modalities, and address unmet needs in chronic pain, rehabilitation, and home-based pain management applications.
- Limited global scale, narrower product portfolios, and lower financial resources compared to large multinational medical device manufacturers. Smaller distribution networks, reduced bargaining power, and lower brand visibility may restrict penetration into large healthcare systems and multinational procurement contracts.
Recent Developments
-
In September 2024, Zynex Inc., a prominent medical technology firm focused on non-invasive devices for pain management and rehabilitation, announced that it has received FDA clearance for its new TensWave device.
-
In September 2024, Nevro Corp., a worldwide medical device company providing extensive, transformative solutions for managing chronic pain, revealed that it received FDA approval and began a confined market release of HFX iQ with HFX AdaptivAI, a tailored, responsive pain management platform that powers the HFX iQ spinal cord stimulation system.
-
In April 2024, Medtronic plc, a worldwide leader in healthcare technology, announced that the Inceptiv closed-loop rechargeable spinal cord stimulator (SCS) has received approval from the U.S. FDA for the management of chronic pain.
Pain Management Devices Market Report Scope
Report Attribute
Details
Market size in 2025
USD 8.4 billion
Estimated market size in 2026
USD 9.2 billion
Projected market size by 2033
USD 16.8 billion
Growth rate
CAGR of 8.9% from 2026 to 2033
Historical data
2021 - 2024
Forecast period
2026 - 2033
Quantitative units
Revenue in USD million/billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Product, Application, End Use, and Region
Regional scope
North America; Europe; Asia Pacific; Latin America; MEA
Country scope
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Norway; Denmark; Sweden; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; Saudi Arabia; South Africa; UAE; Kuwait
Key companies profiled
B Braun Melsungen AG; Baxter; Boston Scientific Corporation; Nevro Corp.; Enovis; OMRON Healthcare INC; Medtronic; ICU Medical Inc; Abott; Stryker
Customization scope
Free report customization (equivalent up to 8 analysts' working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Pain Management Devices Market Segmentation
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the pain management devices market based on product, application, end use, and region:
-
Product Outlook (Revenue, USD Million; 2021 - 2033)
-
Electrical Stimulators
-
TENS
-
Others
-
-
Radiofrequency Ablation
-
Analgesic Infusion Pumps
-
Intrathecal Infusion Pumps
-
External Infusion Pumps
-
-
Neurostimulation
-
Spinal Cord Stimulators
-
Deep Brain Stimulators
-
Sacral Neurostimulators
-
Others
-
-
-
Application Outlook (Revenue, USD Million; 2021 - 2033)
-
Cancer
-
Neuropathic
-
Facial & Migraine
-
Musculoskeletal
-
Trauma
-
Others
-
-
End Use Outlook (Revenue, USD Million; 2021 - 2033)
-
Hospitals & Clinics
-
Physiotherapy Centers
-
Rehabilitation Centers
-
Others
-
-
Regional Outlook (Revenue, USD Million; 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Norway
-
Denmark
-
Sweden
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
South Korea
-
Thailand
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
Saudi Arabia
-
UAE
-
Kuwait
-
-
Research Methodology
The pain management devices market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each pain management devices segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Product
Revenue capture definition
Electrical Stimulators
Devices that use electrical impulses to modulate pain signals, stimulate nerves or muscles, and provide non-pharmacological pain relief. These systems are commonly used for both acute and chronic pain management.
TENS (Transcutaneous Electrical Nerve Stimulation)
Non-invasive electrical stimulation devices that deliver low-voltage electrical currents through electrodes placed on the skin to reduce pain perception by interfering with pain signal transmission and promoting endorphin release.
Others (Electrical Stimulators)
Includes other forms of electrical stimulation technologies such as neuromuscular electrical stimulation (NMES), interferential current therapy, and microcurrent therapy devices used for pain relief and rehabilitation.
Radiofrequency Ablation (RFA)
Minimally invasive devices that use radiofrequency-generated heat to disrupt or destroy targeted nerve tissues responsible for transmitting pain signals. RFA is commonly used for chronic back, neck, joint, and cancer-related pain.
Analgesic Infusion Pumps
Drug delivery systems designed to administer controlled doses of pain-relieving medications directly into the body over a specified period, improving pain control and reducing systemic side effects.
Intrathecal Infusion Pumps
Implantable pumps that deliver analgesic medications directly into the intrathecal space surrounding the spinal cord. These devices are used for severe chronic pain that does not respond adequately to conventional treatments.
External Infusion Pumps
Portable or wearable infusion devices that deliver pain medications through intravenous, subcutaneous, or epidural routes without surgical implantation. They are commonly used in postoperative and cancer pain management.
Neurostimulation
Advanced pain management devices that deliver electrical impulses to specific nerves or regions of the nervous system to modify pain signal transmission and provide long-term pain relief.
Spinal Cord Stimulators (SCS)
Implantable neurostimulation devices that deliver electrical pulses to the spinal cord to block or alter pain signals before they reach the brain. These systems are widely used for chronic neuropathic and back pain conditions.
Deep Brain Stimulators (DBS)
Implantable devices that deliver electrical stimulation to specific areas of the brain to manage certain chronic pain syndromes and neurological disorders when other treatments are ineffective.
Sacral Neurostimulators
Implantable devices that stimulate sacral nerves to manage chronic pelvic pain, lower urinary tract dysfunction, bowel disorders, and related pain conditions.
Others (Neurostimulation)
Includes peripheral nerve stimulators, dorsal root ganglion stimulators, occipital nerve stimulators, and other specialized neurostimulation technologies used in pain management.
Segment - Application
Revenue capture definition
Cancer
Use of pain management devices to alleviate acute and chronic pain associated with cancer progression, metastasis, surgical procedures, chemotherapy, radiation therapy, and palliative care.
Neuropathic
Management of pain resulting from nerve injury or dysfunction, including diabetic neuropathy, postherpetic neuralgia, complex regional pain syndrome (CRPS), failed back surgery syndrome, and peripheral neuropathies.
Facial & Migraine
Application of pain management devices for treating chronic migraines, cluster headaches, trigeminal neuralgia, facial pain syndromes, and other craniofacial pain disorders.
Musculoskeletal
Use of pain management devices for conditions affecting muscles, joints, ligaments, tendons, and bones, including osteoarthritis, rheumatoid arthritis, chronic back pain, neck pain, and sports injuries.
Trauma
Management of pain associated with fractures, soft tissue injuries, surgical recovery, accident-related injuries, and other traumatic conditions requiring acute or long-term pain control.
Others
Includes pain management applications for pelvic pain, postoperative pain, ischemic pain, visceral pain, fibromyalgia, and various chronic pain disorders not classified under other categories.
Segment - End Use
Revenue capture definition
Hospitals and Clinics
Healthcare facilities that diagnose, treat, and manage acute and chronic pain using a wide range of pain management devices, including neurostimulation systems, infusion pumps, and radiofrequency ablation technologies.
Physiotherapy Centers
Specialized rehabilitation facilities that utilize non-invasive pain management technologies such as TENS, electrical stimulation devices, and other therapeutic modalities to reduce pain and improve physical function.
Rehabilitation Centers
Centers focused on restoring physical function and improving quality of life for patients recovering from injuries, surgeries, neurological disorders, or chronic pain conditions through integrated pain management programs.
Others
Includes ambulatory surgery centers, pain management specialty centers, home healthcare settings, long-term care facilities, and research institutions utilizing pain management devices.
Estimation Model
Market Estimation Process:
Market-specific Research Models:
Consensus-Based Estimates & Forecasting
The pain management devices market presents emerging dominant opportunities, featuring global key players such as B Braun Melsungen AG; Baxter; Boston Scientific Corporation; Nevro Corp.; Enovis; OMRON Healthcare INC; Medtronic; ICU Medical Inc; Abott; Stryker; Stimwave LLC. To ensure a holistic approach, the GVR research team adopted a comprehensive methodology, considering multiple companies worldwide and utilizing various variables for data accuracy.
Our methodology included:
Model 1: Commodity Flow Analysis - For public players, annual reports were referenced. For private players, premium paid data sources such as S&P Global, Crunchbase, ZoomInfo, RocketReach, etc., were used for the latest revenue insights.
Model 2: Parent Market Analysis
Model 3: Country-level Multivariate Analysis Assumptions
Model 4: Segment-level Multivariate Analysis Assumptions
Model 5: Pain Management Devices Market CAGR Calculations
Model 1: Commodity Flow Analysis
Commodity flow analysis was employed to track the movement of pain management devices through the value chain, from technology providers to end users. This analysis provided insights into demand generation points, intermediary roles, and ultimate consumption patterns.
Delivered Customizations
This report has been delivered with the following In-depth customizations
CLIENT REQUEST
CUSTOMIZATION DELIVERED
VALUE ADDS
Pain Management Device Adoption & Treatment Utilization Analysis
Developed a tailored analysis of the global pain management devices market focused on neurostimulation devices, spinal cord stimulators (SCS), deep brain stimulators (DBS), sacral neuromodulators, transcutaneous electrical nerve stimulation (TENS) devices, radiofrequency ablation systems, and analgesic infusion pumps. The study assessed adoption trends across hospitals, pain management clinics, ambulatory surgical centers (ASCs), rehabilitation centers, and home healthcare settings while evaluating the growth prevalence of chronic pain, musculoskeletal disorders, cancer-related pain, neuropathic conditions, and increasing demand for non-opioid pain management solutions influencing market growth.
Enables stakeholders to understand evolving pain treatment trends, identify high-growth device categories, assess procedure-driven demand opportunities, and evaluate the impact of technological advancements and changing treatment paradigms on long-term market expansion.
Neuromodulation Technologies, Clinical Outcomes & Minimally Invasive Pain Therapy Assessment
Delivered a customized evaluation of pain management device utilization across chronic back pain, failed back surgery syndrome (FBSS), complex regional pain syndrome (CRPS), neuropathic pain, cancer pain, migraine management, and movement disorder-associated pain conditions. The analysis assessed advancements in closed-loop spinal cord stimulation, wireless neuromodulation systems, high-frequency stimulation technologies, radiofrequency ablation techniques, wearable TENS devices, and programmable infusion pumps. Additional insights evaluated treatment efficacy, patient outcomes, procedural trends, physician adoption patterns, and the role of advanced pain management technologies in reducing opioid dependence and improving quality of life.
Provides actionable insights into commercially attractive therapy segments, emerging neuromodulation technologies, evolving clinical requirements, and growth opportunities associated with improved pain relief outcomes, minimally invasive interventions, enhanced patient satisfaction, and increasing adoption of device-based pain therapies.
Pain Care Infrastructure, Reimbursement Environment & Competitive Landscape Assessment
Included a comprehensive assessment of the pain management devices ecosystem, including device manufacturing, component supply chains, distribution networks, reimbursement frameworks, regulatory approval pathways, healthcare provider adoption, and competitive positioning. The analysis evaluated market access barriers, product innovation strategies, pricing dynamics, clinical evidence requirements, technology adoption trends, quality compliance standards, and competitive differentiation initiatives among leading market participants such as Medtronic, Boston Scientific, Abbott, Nevro, Baxter, B. Braun, Stryker, ICU Medical, OMRON Healthcare, Enovis, and Stimwave.
Supports strategic planning for product development, manufacturing investments, clinical commercialization, healthcare partnerships, geographic expansion, reimbursement optimization, and market entry initiatives by identifying demand drivers, operational challenges, regulatory considerations, revenue opportunities, and competitive advantages across the global pain management devices value chain.
Frequently Asked Questions About This Report
North America dominated with a 47.5% revenue share in 2025.
Asia Pacific is the fastest-growing region over the forecast period.
Neuropathic held the largest revenue share of 32.1% in 2025, while cancer is the fastest-growing area.
Hospitals & clinics held the largest revenue share of 29.8% in 2025, while physiotherapy centers is the fastest-growing area.
The global pain management devices market is expected to grow at a compound annual growth rate of 8.9% from 2026 to 2033 to reach USD 16.8 billion by 2033.
By product, the neurostimulation products segment led with a 57.8% revenue share in 2025, while radiofrequency ablation is the fastest-growing segment.
Some key players operating in the pain management devices market B Braun Melsungen AG; Baxter; Boston Scientific Corporation; Nevro Corp.; Enovis; OMRON Healthcare INC; Medtronic; ICU Medical Inc; Abott; Stryker
The growing prevalence of chronic conditions is one of the key drivers contributing to the market growth during the forecast period. The increasing prevalence of lifestyle diseases, such as diabetes and obesity, has boosted the demand for nerve and muscle stimulators. The rising prevalence of hypertension or trauma is another significant factor expected to propel market growth.
The global pain management devices market size was estimated at USD 8.4 billion in 2025 and is expected to reach USD 9.2 billion in 2026.
About the Author(s)
Medical Devices Research Team
Healthcare · Medical DevicesThis report was authored by the medical devices research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the medical devices segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs — add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
